Copyright 2016 American Medical Association. All Rights Reserved.
Cutaneous effects of obinutuzumab, a glycoengineered anti-CD20 monoclonal antibody, have been rarely reported and there have been no previous reports of a Sweet-like eruption associated with obinutuzumab.
We present a case of a man in his 50s with chronic lymphocytic leukemia (CLL) who developed cutaneous lesions after initiating treatment with obinutuzumab. He had been diagnosed 10 years previously and underwent treatment with fludarabine-cyclophosphamide-rituximab, bendamustine-rituximab, cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP), ibrutinib, ABT-199 (venetoclax), and idelalisib-rituximab. After idelalisib-rituximab failed, he started treatment with obinutuzumab and high-dose methylprednisolone. His other medications included hydrochlorothiazide, metformin, pantoprazole, dapsone, fluconazole, and valacyclovir. Prior to initiating obinutuzumab treatment, he had been experiencing low-grade fevers, nondrenching night sweats, and mild fatigue related to his active CLL.
Korman AM, Hastings JG, Byrd JC, Kaffenberger BH. Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia. JAMA Dermatol. 2017;153(1):108–110. doi:10.1001/jamadermatol.2016.3355
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: